REAL‐WORLD OUTCOMES WITH NOVEL THERAPIES IN R/R DLBCL

Jennifer L. Crombie(Dana-Farber Cancer Institute), Anupama Kalsekar(Bristol-Myers Squibb (United States)), T. Wang(Genmab (United States)), Alex Mutebi(Genmab (United States)), Julie Blædel(Genmab (United States)), A. Chibber(Genmab (United States)), M. Jun(Genmab (United States)), Jon Ukropec(Genmab (United States)), A. Wang(AbbVie (United States)), Rajesh Kamalakar(AbbVie (United States))
Hematological Oncology
June 1, 2023
10.1002/hon.3165_573
Cited by 1

Related Papers

Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma
|Blood|2019|237
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation
|Blood|2019|187
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
|Blood|2024|132
The treatment of Burkitt lymphoma in adults
|Blood|2020|105
Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders
|Frontiers in Oncology|2019|104